$ABEO News

Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule

Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

ABEO: Three Patients Treated in 1Q26 with Two Additional QTCs Activated

Abeona Therapeutics Inc (ABEO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...

Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Transcript

Abeona Therapeutics Q1 Earnings Call Highlights

Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript

Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript

Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network

Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate

Abeona Therapeutics Activates Children's Hospital Of Philadelphia As Sixth Qualified Treatment Center To Treat ZEVASKYN Gene-Modified Cellular Sheets

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point

Abeona Therapeutics Inc. (ABEO) Q4 2025 Earnings Call Transcript

Abeona Therapeutics (NASDAQ:ABEO) Reports First Commercial Revenue and Bolstered Balance Sheet in 2025

Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target